05/05/2021
Marie Skłodowska-Curie Actions

MSCA-PF: Joint application at the University of Granada. Department of Human Embriology and Anatomy

This hosting has expired


  • OFFER DEADLINE
    02/09/2021 14:30 - Europe/Brussels
  • EU RESEARCH FRAMEWORK PROGRAMME
    HE / MSCA
  • LOCATION
    Spain, Granada
  • ORGANISATION/COMPANY
    International Research Projects Office
  • DEPARTMENT
    Promotion and Advisory Unit
  • LABORATORY
    NA

Professor José Carlos Prados Salazar, from the Department of Human Embriology and Anatomy at the University of Granada, welcomes postdoctoral candidates interested in applying for a Marie Skłodowska-Curie Postdoctoral Fellowships (MSCA-PF) in 2021 at this University. Please note that applicants must comply with the Mobility Rule (more information about the 2020 call: http://sl.ugr.es/0aNV, the 2021 call is not yet open).

Brief description of the institution:

The University of Granada (UGR), founded in 1531, is one of the largest and most important universities in Spain. With over 60.000 undergraduate and postgraduate students and 6.000 staff. UGR offers a total of 89 degrees, 110 master’s degrees and 28 doctoral programmes through its 123 departments and 27 centers. Consequently, the UGR offers one of the most extensive and diverse ranges of higher education programmes in Spain.

The UGR has awarded with the "Human Resources Excellence in Research (HRS4R)", which reflects the UGR’s commitment to continuously improve its human resource policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. UGR is also a leading institution in research, located in the top of Spanish universities by a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, or international funding. UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking - Academic Ranking of World Universities (ARWU) (http://sl.ugr.es/0bsW). The UGR is amongst the 201-300 first universities of the world, between 2nd-5th position of Spanish universities and number 1 in the Andalusian Region in the Shanghai Top 500 ranking. Specialties at UGR that stand out are Library & Information Science (position 32) and Food Science & Technology (position 36). Moreover, the UGR is also situated amongst the first 100 universities in Mining & Mineral Engineering between (76th-100th position), in Mathematics (between 76th-100th position) and in Hospitality & Tourism Management (between 76th-100th position). The edition of the ARWU places the UGR in 201-300th position in the world and as the 4th highest ranked University in Spain, reaffirming its position as an institution at the forefront of national and international research.

Additionally, the UGR has 8 researchers at the top of the Highly Cited Researchers (HCR) list in Computer Sciences & Engineering (position 101-150). It is also well recognized for its web presence (http://sl.ugr.es/0a6i), being positioned at 43th place in the top 200 Universities in Europe.

Internationally, we bet decidedly by our participation in the calls of the Framework Programme of the European Union. For the duration of the last two Framework Programmes, the UGR has obtained a total of 67 projects, with total funding of 18.029 million euros, and for H2020, 118 projects with total funding around 29.115 million euros.

Brief description of the Centre/Research Group:

The Research Group "New Therapies Applied to Research in Biomedicine" (CTS 107) is a multidisciplinary group with a total of 19 basic and clinical researchers (doctors, clinical oncologists, biochemists, nanotechnologists, biologists, pharmacists, biotechnologists and bioinformatics). Our Group has stable relationship with others Biomedicine and Cancer Centers (Switzerland, UK, Italy and Portugal, among others) and pharmaceutical companies (ROCHE-FARMA S.A and ESTEVE S.L.) and has a clear vocation for clinical application of the results to improve the quality of cancer patient life. Our research activity, continuously funded since 1990, is currently focused on three research lines: 1) New biomarkers for cancer detection, 2) New strategies for cancer treatment: nanotechnology and gene therapy and 3) Cancer and Nutrition. We has obtained relevant achievements published in high impact journals (see results in web), among which we can highlight some that has been patented: 1) to discover new (RNA, proteins and recently metabolites) tumor markers for pancreatic cancer (international patents WO 2014/076342 and WO/2014/198995 and solicited patent P201930559), 2) to determine the application of sigma ligands against cancer (patent WO/2017/21176), 3) to develop of new nanodrugs with doxorubicin and 5-FU in collaboration with the Hospital Virgen de las Nieves which were patented (WO 2012/104461A1 and PCT/ES2014/070941) and 4) to develop for the first time in the world antitumor therapies using the suicide Gef and E genes (WO2015/011332 A1 and W02009/133220).

Project description:

Our Project is named BIO-PAN-CAN. Its aim is to use a massive sequencing technique in peripheral blood samples from patients with pancreatic adenocarcinoma (PAD) to determine a sensitive and specific biomarker which can be clinically used to its early detection.

PAD diagnosis usually occurs in an advance stage with the presence of tissue infiltration or metastasis that make the tumour unresectable. In fact, the PAD prognosis is very poor with survival rates of 5% at the first 5 years. In this context, massive sequencing technology allows the simultaneously analysis of thousands of genes in cancer samples in a fast, reproducible and less and less expensive way.

Previous results of our Group demonstrated that the gene expression in peripheral blood of patients with PAD show a different expression pattern from that presented in healthy subjects and that this pattern can be used for its diagnosis. The pattern includes genes such as IRAK3 and CLEC4D (WO/2014/198995). In this ambitious, multidisciplinary (Information Technologies Research Centre and Biomedical Research Centre from Granada) and multicentric Project, five General Hospitals participate to assure the number of samples (peripheral blood) in order to 1) obtain total RNA and carry out RNASeq, 2) analyse big-data and determine pattern of differentially expressed genes; 3) carry out a blind validation study of the differential expression profile by digital PCR, and 4) establish the correlation between proposed markers and clinical-pathological variables of patients with ADP. The success of the Project will allow to obtain a new tool to the ADP early diagnosis that could represent a great clinical advance due to the possibility of starting treatment earlier improving the prognosis of these patients.

Research Area:

  • Information Science and Engineering (ENG)
  • Life Sciences (LIFE)

For a correct evaluation of your candidature, please send the documents below to Professor José Carlos Prados Salazar (jcprados@ugr.es):

  • CV
  • Letter of recommendation (optional)

Disclaimer:

The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.